Impact of age on the efficacy of bone marrow mononuclear cell transplantation in experimental stroke

Experimental & Translational Stroke Medicine

Johannes Boltze⁵  Gesa Weise⁵  Alexander Kranz⁵  Markus Scholz⁴  Dirk Hasenclever⁴  Alexander Kaminski³  Cornelia Voigt¹  Marlene Lorenz²  Myriam Peters²  Mitja Bojko²  Daniel-Christoph Wagner⁵ 

[1] Department of Urology, University of Leipzig, Leipzig, Germany;Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany;Department of Cardiac Surgery, University of Rostock, Rostock, Germany;Institute for Medical Informatics, Statistics & Epidemiology, University of Leipzig, Leipzig, Germany;Translational Centre for Regenerative Medicine, University of Leipzig, Leipzig, Germany

关键词: SHR;    Comorbidity;    Age;    Bone marrow cell transplantation;    Cell transplantation;    Brain ischemia;   

Others  :  861800
DOI  :  10.1186/2040-7378-4-17

 received in 2012-07-28, accepted in 2012-08-21,  发布年份 2012

【 摘 要 】

Bone marrow-derived mononuclear cells (BM MNC) have been effectively used to treat experimental stroke. Most of the preclinical trials have been performed in young and healthy laboratory animals, even though age and hypertension are major risk factors for stroke. To determine the influence of age on the properties of BM MNCs after cerebral ischemia, we compared the efficacy of aged and young BM MNC in an in vitro model of cerebral hypoxia and in an adapted in vivo model of stroke. Human BM MNCs were obtained from healthy young or aged donors and either co-cultured with rat hippocampal slices exposed to oxygen glucose deprivation (OGD), or transplanted intravenously 24 h after permanent middle cerebral artery occlusion in aged (18 months) spontaneously hypertensive rats (SHR). Efficacy was examined by quantification of hippocampal cell death, or respectively, by neurofunctional tests and MR investigations. Co-cultivation with young, but not with aged BM MNCs significantly reduced the hippocampal cell death after OGD. Transplantation of both young and old BM MNCs did not reduce functional deficits or ischemic lesion volume after stroke in aged SHR. These results suggest a significant impact of age on the therapeutic efficacy of BM MNCs after cerebral ischemia.

【 授权许可】

   
2012 Wagner et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM: Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001, 56:1015-1020.
• [2]Chopp M, Li Y, Zhang ZG: Mechanisms underlying improved recovery of neurological function after stroke in the rodent after treatment with neurorestorative cell-based therapies. Stroke 2009, 40:S143-S145.
• [3]Savitz SI, Misra V: Launching intravenous bone marrow cell trials for acute stroke. Regen Med 2009, 4:639-641.
• [4]Savitz SI, Misra V, Kasam M, Juneja H, Cox CS Jr, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC: Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol 2011, 70:59-69.
• [5]Brenneman M, Sharma S, Harting M, Strong R, Cox CS Jr, Aronowski J, Grotta JC, Savitz SI: Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J Cereb Blood Flow Metab 2010, 30:140-149.
• [6]Giraldi-Guimaraes A, Rezende-Lima M, Bruno FP, Mendez-Otero R: Treatment with bone marrow mononuclear cells induces functional recovery and decreases neurodegeneration after sensorimotor cortical ischemia in rats. Brain Res 2009, 1266:108-120.
• [7]Yoshihara T, Ohta M, Itokazu Y, Matsumoto N, Dezawa M, Suzuki Y, Taguchi A, Watanabe Y, Adachi Y, Ikehara S, Sugimoto H, Ide C: Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury. J Neurotrauma 2007, 24:1026-1036.
• [8]Iihoshi S, Honmou O, Houkin K, Hashi K, Kocsis JD: A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res 2004, 1007:1-9.
• [9]Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, Wolf PA: The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006, 37:345-350.
• [10]Stoppini L, Buchs PA, Muller D: A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 1991, 37:173-182.
• [11]Sarnowska A, Braun H, Sauerzweig S, Reymann KG: The neuroprotective effect of bone marrow stem cells is not dependent on direct cell contact with hypoxic injured tissue. Exp Neurol 2009, 215:317-327.
• [12]Riegelsberger UM, Deten A, Posel C, Zille M, Kranz A, Boltze J, Wagner DC: Intravenous human umbilical cord blood transplantation for stroke: Impact on infarct volume and caspase-3-dependent cell death in spontaneously hypertensive rats. Exp Neurol 2011, 227:218-223.
• [13]Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, Sanchez-Ramos J, Chopp M: Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001, 32:2682-2688.
• [14]Metz GA, Whishaw IQ: Cortical and subcortical lesions impair skilled walking in the ladder rung walking test: a new task to evaluate fore- and hindlimb stepping, placing, and co-ordination. J Neurosci Methods 2002, 115:169-179.
• [15]Kranz A, Wagner DC, Kamprad M, Scholz M, Schmidt UR, Nitzsche F, Aberman Z, Emmrich F, Riegelsberger UM, Boltze J: Transplantation of placenta-derived mesenchymal stromal cells upon experimental stroke in rats. Brain Res 2010, 1315:128-136.
• [16]Matthews JN, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ 1990, 300:230-235.
• [17]Sharma S, Yang B, Strong R, Xi X, Brenneman M, Grotta JC, Aronowski J, Savitz SI: Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic stroke. J Neurosci Res 2010, 88:2869-2876.
• [18]Chopp M, Li Y: Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002, 1:92-100.
• [19]Tate CC, Fonck C, McGrogan M, Case CC: Human mesenchymal stromal cells and their derivative, SB623 cells, rescue neural cells via trophic support following in vitro ischemia. Cell Transplant 2010, 19:973-984.
• [20]Stolzing A, Jones E, McGonagle D, Scutt A: Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008, 129:163-173.
• [21]Popa-Wagner A, Badan I, Walker L, Groppa S, Patrana N, Kessler C: Accelerated infarct development, cytogenesis and apoptosis following transient cerebral ischemia in aged rats. Acta Neuropathol 2007, 113:277-293.
• [22]Badan I, Buchhold B, Hamm A, Gratz M, Walker LC, Platt D, Kessler C, Popa-Wagner A: Accelerated glial reactivity to stroke in aged rats correlates with reduced functional recovery. J Cereb Blood Flow Metab 2003, 23:845-854.
• [23]Li S, Zheng J, Carmichael ST: Increased oxidative protein and DNA damage but decreased stress response in the aged brain following experimental stroke. Neurobiol Dis 2005, 18:432-440.
• [24]Popa-Wagner A, Dinca I, Yalikun S, Walker L, Kroemer H, Kessler C: Accelerated delimitation of the infarct zone by capillary-derived nestin-positive cells in aged rats. Curr Neurovasc Res 2006, 3:3-13.
• [25]Li S, Carmichael ST: Growth-associated gene and protein expression in the region of axonal sprouting in the aged brain after stroke. Neurobiol Dis 2006, 23:362-373.
• [26]Bliss TM, Andres RH, Steinberg GK: Optimizing the success of cell transplantation therapy for stroke. Neurobiol Dis 2010, 37:275-283.
• [27]Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew AP, Barone FC: SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Exp Neurol 2008, 212:53-62.
• [28]Pantoni L: Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010, 9:689-701.
• [29]Nicol A, Nieda M, Donaldson C, Denning-Kendall P, Truman C, Bradley B, Hows J: Cryopreserved human bone marrow stroma is fully functional in vitro. Br J Haematol 1996, 94:258-265.
• [30]Schmidt-Mende J, Hellström-Lindberg E, Joseph B, Zhivotovsky B: Freezing induces artificial cleavage of apoptosis-related proteins in human bone marrow cells. J Immunol Methods 2000, 245:91-94.
• [31]Yang B, Strong R, Sharma S, Brenneman M, Mallikarjunarao K, Xi X, Grotta JC, Aronowski J, Savitz SI: Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke. J Neurosci Res 2011, 89:833-839.
• [32]Thum T, Bauersachs J, Poole-Wilson PA, Volk HD, Anker SD: The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol 2005, 46:1799-1802.
• [33]Sullivan PG, Sebastian AH, Hall ED: Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury. J Neurotrauma 2011, 28:311-318.
• [34]Chamorro A, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R: The immunology of acute stroke. Nat Rev Neurol 2012, 8:401-410.
• [35]Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki K, Duan J, Imaizumi T: Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 2001, 103:897-903.
• [36]Zhang S, Guo J, Zhang P, Liu Y, Jia Z, Ma K, Li W, Li L, Zhou C: Long-term effects of bone marrow mononuclear cell transplantation on left ventricular function and remodeling in rats. Life Sci 2004, 74:2853-2864.
• [37]Fujita Y, Ihara M, Ushiki T, Hirai H, Kizaka-Kondoh S, Hiraoka M, Ito H, Takahashi R: Early Protective Effect of Bone Marrow Mononuclear Cells Against Ischemic White Matter Damage Through Augmentation of Cerebral Blood Flow. Stroke 2010, 41:2938-2943.
• [38]Zhuo Y, Li SH, Chen MS, Wu J, Kinkaid HY, Fazel S, Weisel RD, Li RK: Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg 2010, 139:1286-1294.
• [39]Sugihara S, Yamamoto Y, Matsuura T, Narazaki G, Yamasaki A, Igawa G, Matsubara K, Miake J, Igawa O, Shigemasa C, Hisatome I: Age-related BM-MNC dysfunction hampers neovascularization. Mech Ageing Dev 2007, 128:511-516.
• [40]Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, Sadamoto K, Horii M, Matsumoto T, Murasawa S, Shibata T, Suehiro S, Asahara T: Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation 2006, 113:1311-1325.
• [41]Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, Tsukamoto Y, Iso H, Fujimori Y, Stern DM, Naritomi H, Matsuyama T: Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004, 114:330-338.